Pharma patents 'are stifling stem cell research'
Stem cell research is suffering from pharma patent proliferation, it is claimed

Bioanalytical

Pharma patents 'are stifling stem cell research'

17 Feb, 2011

Published over 15 years ago. See the latest and most current information on Bioanalytical.

Research into stem cell technologies is being stifled by the proliferation of pharma patents in the field, it is claimed.

Scientists at Johns Hopkins Medical Institutions claim that allowing pharma developers to privatise stem cell lines and related data is damaging to innovation as a whole.

"Pervasive taking of intellectual property rights has resulted in a complex and confusing patchwork of ownership and control in the field of stem cell science," says bioethicist Dr Debra Mathews, assistant director for science programmes at the Berman Institute.

She adds that the pharma industry must strike a balance between transparency of research outcomes and the incentive provided by the right to patent intellectual property relating to discoveries.

Without proper management of this process, she warns that the concept of what counts as 'in the public domain' could become difficult to define.

Johns Hopkins Medical Institutions bring together scientists from a broad health system valued at around $5 billion (£3 billion) to allow physicians and researchers to collaborate with one another.

Latest News

Explore Our Other Sites

Labmate Online
Metrohm launches OMNIS IC: a new benchmark in ion chromatography
Explore more Arrow
Envirotech Online
Vehicle-based methane detection system passes German suitability test
Explore more Arrow
Pollution Solutions Online
Large-scale liquefied biogas bunkering to become possible in the Port of Gothenburg in 2027
Explore more Arrow
Petro Online
Hydrogen sulphide deaths expose the gaps in gas detection during non-routine work
Explore more Arrow